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Abstract
Background: Chagas disease caused by the protozoan Trypanosoma cruzi is an important public health problem in Latin
America. The immunological mechanisms involved in Chagas disease pathogenesis remain incompletely elucidated. The
aim of this study was to explore cytokine profiles and their possible association to the infecting DTU and the pathogenesis
of Chagas disease.
Methods: 109 sero-positive T. cruzi patients and 21 negative controls from Bolivia and Colombia, were included. Flow
cytometry assays for 13 cytokines were conducted on human sera. Patients were divided into two groups: in one we
compared the quantification of cytokines between patients with and without chronic cardiomyopathy; in second group we
compared the levels of cytokines and the genetic variability of T. cruzi.
Results: Significant difference in anti-inflammatory and pro-inflammatory cytokines profiles was observed between the two
groups cardiac and non-cardiac. Moreover, serum levels of IFN-c, IL-12, IL-22 and IL-10 presented an association with the
genetic variability of T.cruzi, with significant differences in TcI and mixed infections TcI/TcII.
Conclusion: Expression of anti-inflammatory and pro-inflammatory cytokines may play a relevant role in determining the
clinical presentation of chronic patients with Chagas disease and suggests the occurrence of specific immune responses,
probably associated to different T. cruzi DTUs.
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Introduction
Chagas disease is considered by the World Health Organization
(WHO) as one of the most important public health problems in
Latin America, with an estimate of 7 million people infected and
110 million people at risk of contracting the disease [1,2]. Recent
evidence has also indicated that Chagas disease has migrated to
non-endemic regions posing a significant social threat [3]. This
parasitic disease is caused by the protozoan Trypanosoma cruzi,
transmitted by different routes: via the feces of infected triatomine
bugs, contaminated blood transfusion, oral (contaminated food/
juices), vertical transmission, organs transplantation and laborato-
ry accidents. Approximately 60% of patients in the chronic phase
are clinically asymptomatic, around 30% manifest cardiomyopa-
thy, 8% megavisceral syndromes and the remaining 2% both
cardiomyopathy and digestive involvement [4,5,6,7].
Two main hypotheses regarding the pathogenesis of Chagas
disease have been proposed. One based on parasite persistence,
and a second hypothesis based on adverse human host immune
response to the infection, causing autoimmune aggression [8]. In
the acute phase of the disease the host is able to control the
infection in three different but complementary ways: i) Detection
and direct destruction of the parasite by cells such as macrophages
and dendritic cells, ii) activation of dendritic cells and macro-
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e91154
phages that present antigen stimulation for the activation of the
antigen-specific immune responses and iii) detection of infection by
non-hematopoietic cells, which are the principal targets of the
invasion by T. cruzi [9]. In the chronic phase, antigens that are
elicited by the immune response are mediated by T cells, which
play an important role in the progression of the disease. Studies in
children with the indeterminate form have shown a high frequency
of pro-inflammatory monocytes and regulatory cells compared
with healthy subjects [10]. Thus, it is believed that expression of
cytokines and their kinetics are important key factors influencing
the development and progression of the disease. In fact, the
balance between excessive pro-inflammatory cytokines and anti-
inflammatory cytokines may be critical in the development of the
chronic phase of the disease [5,8,11]. Studies on the specific role of
cytokines in the immune response against T. cruzi have been
recently reported and demonstrate that large amounts of Th1 pro-
inflammatory cytokines such as Interferon Gamma (IFN-c),
Tumor Necrosis Factor Alpha (TNF-a) are related to cardiac
disease [12]. It is also known that these cytokines are regulated by
anti-inflammatory cytokines in low concentrations such as
interleukin 10 and 5 (IL-10 and IL-5) [13]. Altogether, these data
suggest a link between parasite infection, immune response
polarization, and specific organ damage. Thus, cytokines may be
used as biomarkers in order to identify the immune factors that
influence disease progression has been carried out in different
pathologies such as malaria, yellow fever, HIV infection, and also
in Chagas disease [14,15,16]. It is believed that in these infectious
diseases deregulation of host inflammatory responses play an
important role and the profile of cytokines may be used as
biomarkers of disease progression. Consequently, the character-
ization of these profiles may lead to future selection of treatment
strategies targeting specific inflammatory pathways [17].
Several investigators have attempted to associate T. cruzi genetic
variability and the different clinical manifestations of Chagas
disease. The genetic variability within the T. cruzi taxon has been
demonstrated using biological, biochemical and molecular mark-
ers, and has been grouped into six Discrete Typing Units (DTUs),
TcI-TcVI [18,19]. TcI is mostly related to the sylvatic cycle in the
Amazon region with sporadic cases in the domestic foci recently
named TcIDOM [20]. However, TcI has recently gained relevance
since it has been associated with severe cardiomyopathic
manifestations in patients from Argentina and Colombia
[19,21,22,23]. TcII is the principal agent of Chagas disease in
the Southern Cone of America and Triatomainfestans is the principal
vector. TcV and TcVI, are derived from the hybridization
between TcIII and TcII/TcIV and the cycle of transmission is
mainly domestic [18,24]. These DTUs are related not only to
heart disease but also to megavisceral syndromes [25,26]. TcIII
and TcIV are mainly related to the sylvatic cycle of transmission
and scarce evidence of human infection has been reported
[27,28,29].
The aim of this study was to evaluate the different cytokine
profiles in Chagasic patients with and without chronic cardiomy-
opathy to correlate these cytokine profiles in patients infected with
the different T.cruziDTUs in order to establish whether these
factors may be involved in the pathogenesis of Chagas disease.
Our results show that specific anti-inflammatory and pro-
inflammatory cytokine modulation is correlated with the clinical
presentation of chronic patients with Chagas disease and suggests
the occurrence of specific immune responses, probably associated
to different T. cruzi DTUs.
Results
Signature Profiles
Group I: CARD vs. NON-CARD. To identify possible
markers of infection, and more specifically of cardiomyopathy,
we measured seric cytokines in 16 patients with cardiomyopathy
(CARD), 38 non-cardiac chagasic patients (NON-CARD), and 9
non-infected individuals (CONTROL). As expected in the case of
immune responses against infection, cytokine production greatly
varies among individuals, rendering inaccurate the use of the
mean as central indicator. We thus used the mean of cytokine
concentration, the latter being evaluated by the mean fluorescence
intensity (MFI) of beads bound to cytokines recognized by
immunofluorescence. The overall median of each individual
MFI cytokine was calculated (IL-1b= 63.32, IL-2 = 49.28, IL-
4 = 45.92, IL-5 = 58.24, IL-6 = 276, IL-9 = 181.4, IL-10 = 85.68,
IL-12p70 = 54.6, IL-13 = 33.04, IL-17A = 44.8, IL-22 = 82.88,
IFN-c= 48.8 and TNF-a= 108.6) from patients of different
clusters. These values were used as the cut-off mark to tag the
cell population from each patient as being a high or low cytokine
producer (Figure S1 in File S1). Then, in each group and for each
cytokine, results were expressed as the frequency of individuals
with a concentration of seric cytokine higher than the median of all
samples (Figure 1). The assembling of the ascendant frequency of
high cytokine producers for CONTROL generated the reference
cytokine signature applied to identify changes in the overall
cytokine signature from the CARD and NON-CARD groups. The
results showed that the frequency of high cytokine producers in the
CARD and NON-CARD groups was lower than in the
CONTROL group.
A switch among anti-inflammatory and pro-inflammatory
cytokines profiles in the CARD and NON-CARD groups of
patients was observed. The NON-CARD patients showed higher
frequency of anti-inflammatory cytokines and lower frequency of
pro-inflammatory cytokines while the CARD displayed higher
pro-inflammatory and lower anti-inflammatory cytokines. The
cytokines involved in the anti-inflammatory profile were IL-13, IL-
5 and IL-10 and those in the pro-inflammatory profile were: IL-2,
IL-6, IL-9 and IL12 (FIGURE 2).
Group II: T. cruzi variability. As for Group I,overallme-
dian of each MFI cytokine wascalculated (IL-1b= 292,32, IL-
2 = 224, IL-4 = 209.44, IL-5 = 251.44, IL-6 = 1197, IL-9 = 792.4,
IL-10 = 369.6, IL-12p70 = 228.48, IL-13 = 160.16, IL-
17A = 207.76, IL-22 = 547.12, IFN-c= 198.24 and TNF-
a= 465.92). These values were used as the cut-off mark to tag
the cell population from each patient as being a high or low high
cytokine producers(Figure S2 in File S1). Assembling of the
ascendant frequency of high cytokine producers for CONTROL
generated the reference cytokine signature applied to identify
changes in the overall cytokine signature from all other groups:
TcI, TcII and Mixed TcI/TcII (FIGURE 3).
A pro-inflammatory pattern was observed for all infected
groups, but no particular pattern could be associated to the
different DTUs. The frequency of cytokines in TcI, TcII and
Mixed TcI/TcII showed lower frequency as compared with the
CONTROL levels.
All the quantitative results provided by the cytometry system are
included and can be found in Tables S1 and S2 in File S2.
Statistical Analysis
This analysis aimed to establish associations between levels of
cytokines and the clinical manifestation (CARD or IND) and/or
the genetic variability of T.cruzi (TcI, TcII and Mixed TcI/TcII).
Analysis of principal components was performed with the 13
Cytokine Profiling in Chagas Disease
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cytokines studied. The principal components for the study group
CARD vs NON-CARD were IL-12 = 0.990, IFN-c= 0.990, IL-
1 = 0.920, IL-6 = 0.915 and IL-9 = 0.895 which explained the
model in 80.4% of the variation in the dataset; for the study group
II T. cruzi DTUs the principal components were IFN-c= 0.882,
IL-12 = 0.822, IL-22 = 0.817 and IL-10 = 0.805 explaining
75.42% of variation (Tables S3 to S8 in File S2).
Finally, discriminant analysis was performed to observe which
proportion of the selected components were actually able to group
the study groups; for study group I (CARD vs NON-CARD) the
components group in the right cluster (when both real and theory
group coincide) : NON-CARD = 21/38 (55.3%), CAR = 16/16
(100%) and CONTROL = 5/9 (55.6%) (FIGURE 4 a); and for the
study group II (T. cruzi DTUs) the components group in the right
cluster TcI = 19/20 (95%), TcII = 3/20(15%), Mixed TcI/
II = 13/15(86,7%) and CONTROL = 10/12(83,3%) (FIGURE 4
b). These results show a clear profile in patients with CARD, and
an association between levels of cytokines and the variability of
T.cruzi (TcI, TcII and Mix TcI/TcII)(Tables S9 and S10 in File
S2.).
Discussion
An important finding of this study was a switch between the
anti-inflammatory cytokines IL-13, IL-5 and IL-10 and pro-
inflammatory cytokines IL-2, IL-6, IL-9 and IL-12 among CARD
and NON-CARD groups. These findings suggest that regulation
(differential regulation of cytokine synthesis) may play an
important role in the development of Chagas cardiomyopathy.
The anti-inflammatory/pro-inflammatory cytokine profile
switch found between patients with Chagas cardiomyopathy and
those infected but still in the NON-CARD stage of the disease is
compatible with the hypothesis that the progression of human
Chagas disease from asymptomatic to severe forms, is related with
a lack of adequate immune modulation [8]. While an appropriate,
inflammatory, response may be beneficial in early stages of
infection, the lack of control of this response later on the outcome
of the disease will allow for the establishment of tissue damage.
This hypothesis is in agreement with the finding that IL-10 levels
were diminished in comparison to levels of TNF- a and IFN-c in
CARD patients, in contrast with the opposite profile (higher levels
of IL-10 than levels of TNF- a and IFN-c) in indeterminate form
patients [8]. These findings are also in keeping with a recent report
documenting increased matrix metalloproteinases 2 and 9 in T.
cruziseropositive subjects with and without Chagas cardiomyopa-
Figure 1. Cytokine Signatures with Frequency of Subjects with High Cytokine Levels. The diagrams were plotted using the global median
of each MFI cytokine index as the cut-off mark to identify higher levels. The ascendant frequency of high cytokine producers at the with (CARD) and
without Chagas cardiomyopathy (NON-CARD) was demonstrated by bar graphics. The ascendant frequency of high cytokine producers of the
CONTROL group was used to generate the reference cytokine signature curves that were applied to identify changes in the overall cytokine signature
from all other groups.
doi:10.1371/journal.pone.0091154.g001
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thy manifestations [30]. However, previous reports have not
documented that these pro-inflammatory cytokines play an
important role in producing Chagas disease immunomodulation
disequilibrium [8,31,32].
Pro-inflammatory cytokines involved in the switch were IL-2,
IL-9, IL-6 and IL-12. The role of the last two cytokines has already
been studied in Chagas disease. Thus, the presence of high levels
of IL-6 in CARD patients was correlated with the severity of
myocardium damage, in Peruvian and Colombian populations
[33]. Another study determined the role of genetic polymorphism
in the IL-12, and it was the C allele of IL-12B 39UTR that acted as
a risk factor and influenced the susceptibility to develop
cardiomyopathy in Chagas disease [34]. Our results are in
agreement with these studies and additionally document that
these cytokines have higher levels in CARD patients compared to
NON-CARD patients. On the other hand, the anti-inflammatory
cytokines involved in the switch were IL-13, IL-5 and IL-10. IL-10
was the most important anti-inflammatory cytokine studied in the
Chagas disease, and it has been shown that NON-CARD patients
display higher levels of IL-10 in comparison to cardiac patients
[8,35]. Other investigators evaluated the SNP’s in indeterminate
and CARD populations, and also divided the cardiac patients
between those with non-dilated and dilated hearts, finding
different allele and genotype frequencies among them; also, a
correlation was found between the allele A of -1082G/A in the IL-
10 and low levels in CARD patients [36].
On the other hand, the relationship of the genetic variability of
the parasite and host characteristics with pathogenesis is increas-
ingly recognized as an important factor in the understanding of
Chagas disease. In all our groups independent of the genetic
variability of the infecting T.cruzi DTUs a pro-inflammatory
profile was observed. Moreover, all those groups manifested a pro-
inflammatory profile similar to the one we found in the study
group I (CARD and NON-CARD). However, the TcII and Mixed
groups showed higher levels of cytokines compared to the TcI,
where the levels did not exceed 50%. It is interesting to speculate
that the lack of a highly specific profile associated to a particular
infecting-DTU is likely due the pleiotropic and somewhat
redundant role of many cytokines. For all DTUs groups the
profile is pro-inflammatory, and probably this pro-inflammatory
profile will eventually lead to the same clinical manifestation
(cardiomyopathy), regardless of the different DTUs with which the
patients were infected and of some particular cytokine responses
which are DTU-dependent. Thus, we found higher levels of the
cytokines IL-6 for TcI, IL-1 for TcII and of IL-22 for Mixed TcI/
TcII. This is relevant, since it is known that IL-6 is secreted by T
cells and macrophages, IL-1 by macrophages and lymphocytes,
and IL-22 by dendritic cells and T cells [37].
Presumably, DTU-specific recognition by the immune system
(Antibodies, B cells, or T cells), could lead to the differential
responses observed. Thus the DTUs-differential recognition by
host receptors, that recognized pathogen patterns and their
cognate pathogen associated molecular patterns (PAMPs), could
be linked with the observed different induction of pro-inflamma-
tory cytokines. In this regard, previous reports, demonstrated that
GPI-anchors from T.cruzi surface antigens triggered the synthesis
Figure 2. Comparative Cytokine Signatures of NON-CARD and CARD. The diagram is a comparison between the signing of the NON-CARD
(&) and CARD (&). There is a switch between pro-inflammatory with the boxes in solid line (IL-6, IL-2, IL-9 and IL-12) and anti-inflammatory with the
boxes in dashed line (IL-5,IL-13 and IL-10) cytokines; the CARD have higher frequencies of proinflammatory cytokines and lower levels of
inflammatory cytokines, whereas the opposite occurs in the case of NON-CARD.
doi:10.1371/journal.pone.0091154.g002
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of IL-12 by macrophages and dendritic cells through toll-like
receptor 2 (TLR-2) dependent activation [38]. In addition, TLR-9
that recognizes T. cruziCpG-rich DNA also stimulated the
production of IL-12, IFN-c and TNF-a by macrophages. The
glycoinositolphospholipid from epimastigotes of T. cruzi is recog-
nized as TLR-4 in which also trigger IL-12, IL-2 and TNF. In
addition, other cells, known to be infected T. cruzi, as myocytes
and adipocytes, may contribute to the cytokine profile observed.
Since IL-6 is also produced by adipocytes [9].
The DAPC analysis showed a clear grouping for the CARD
patients but not for NON-CARD patients. This result may be due
to the fact that some patients in the NON-CARD group could be
eventually more predisposed to develop cardiomyopathy or mega-
viscera syndrome explaining why cytokine levels are not homo-
geneous for this group. In the study group, the DAPC analysis
suggests that there is association between the genetic variability of
T. cruzi (Tc I, Tc II and Mixed TcI/TcII) and the levels of some
cytokines. We found again in both groups, I and II, that IL-12,
IFN-c, IL-6 and IL-1 are the principal components and thus they
may play an important role in Chagas disease pathophysiology.
Also, differences in the frequency of high producers of IL-17
among in patients infected with different DTUs were found: 0%
for TcI, 60% for TcII and 40% for mixed infection (TcI/TcII).
Those differences may lead to slightly different outcomes of the
disease. In this regard, previous studies showed that patients with
less aggressive cardiomyopathy forms of the disease produce
higher levels of IL-17 [39], suggesting that in our study the patients
with more severe cardiomyopathy infection would be those with
TcI followed by those with mixed infection and finally those
infected with TcII.
In summary, pro-inflammatory profile is associated to CARD
patients and anti-inflammatory profile to NON-CARD patients.
The fact that the levels of cytokines were different for patients
infected with different parasite DTUs suggests a specific immune
response, probably associated to DTUs. A novel contribution of
this study is the possibility of using IL-12, IFN-c, IL-6 and IL-1 as
prognostic biomarkers of Chagas Disease. Future studies should be
carried out covering the geographical wide-range of DTUs and
other human populations, in order to validate these cytokines as
biomarkers as well as finding the plausible association between
DTUs-epitope and Chagas Disease clinical manifestations.
Figure 3. Comparison of Immunological Signatures between patients with chronic chagasic cardiomyopathy infected with different
DTU’s. The diagram is a comparison between the signing of the TcI (&), Tc II (&), Mixed TcI+TcII (&) and CONTROL (%). Cytokines with frequency
equal or higher than 50% are in boxes.
doi:10.1371/journal.pone.0091154.g003
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Materials and Methods
Human Sera
Following WHO criteria for Chagas disease diagnosis, two
serological tests (ELISA and IIF) were employed to enroll the
patients. According to these diagnostic test results, a total of 109
serum samples from Chagas patients and 21 serum samples from
healthy donors were assayed, aged 40 to 50 years living in rural
areas of Colombia and Bolivia (77 individuals from Santander,
Colombia and 53 from Cochabamba and Tarija, Bolivia). Chagas
patients were classified as without cardiomyopathy (NON-CARD
= 38) when they were seropositive with no evidence of cardiac
disease (based on the absence of symptoms, physical signs and of
normal X-ray, electrocardiogram and/or echocardiogram). Pa-
tients with chronic Chagas cardiomyopathy (CARD = 71) were
characterized according to clinical criteria and abnormalities in
chest X-ray, electrocardiogram and/or echocardiogram. The
presence of other acute, hepatic, renal or psychiatric diseases
were a motive for exclusion criteria.
The studies were conducted in two groups of individuals: the
first one to compare the differences in the quantification of
cytokines in patients with and without chronic cardiomyopathy
and control individuals; and the second one to compare the
differences between the levels of cytokines and the genetic
variability of T. cruzi.
Group I (CARD and NON-CARD), included 54 serum samples
from Chagas patients, 38 being classified as NON-CARD and 16
patients as CARD, and 9 serum samples from CONTROL
individuals. The selection criteria of the patients groups were
trying based on the assumption of obtaining the percentage to
simulate the % of Chronic Chagasic manifestation reports 38/54
chagasicpatientes (70.37% NON-CARD) against not Chronic
Chagasicmanifestationnd 16/54 (29.62% CARD).
Group II (T. cruzi DTUs), included 55 serum samples from
Chagas patients with chronic cardiomyopathy and 12 CON-
TROL individuals. Twenty patients were typed as TcI, 20 as TcII
and 15 mixed TcI/II. These sera were previously genotyped by
Ramirez et al. 2010, where the initial sample size was 240 patients.
Only 20/240 patients were genotyped as Mixed infection being
TcI+ TcII (5/20 sera were contaminated with bacteria and
subsequently excluded)we use the same sample size of patients for
the others DTUs for optimal statistical analyzes.
Experimental ethics. Written and oral consent was obtained
in all patients included as part of the BENEFIT trial (Benznidazole
Evaluation for Interrupting Trypanosomiasis), the study is
approved by all local and national Institutional Review Board
(ClinicaAboodShaio, Hospital de la Policia, Fundacion Cardio-
vascular de San Gil Santander), the study is approved by the
Ethics Research Committe of the World Health Organization as
one of the funding agencies of the BENEFIT trial.
Cytokine Quantification and Flow Cytometry Acquisition
Fluorescent bead-based flow cytometry assays for 13 anti-
inflammatory and pro-inflammatory cytokines was performed by
duplicate (Human Th1/Th2/Th9/Th17/Th22 13plex FlowCy-
tomix Multiplex, Bender MedSystems GmbH, eBioscience), on
human sera (without in-vitro stimulation), following the manufac-
turer’s protocol. Briefly, combining 2 different bead sizes and 6 or
7 fluorochrome densities for each population (thus fluorescence
intensities, with an emission maximum in the far red range), 13
different bead populations are defined, each one associated to a
specific antibody. Cytokines are trapped by these antibody-bead
Figure 4. Discriminant Analysis of Principal Components (DAPC). 4A. DAPC for with and without cardiomyopathy Chagas patients and
CONTROLS. The diagram show a cluster of 100% for CARD (Red circle), 55,3% for NON-CAR (Cian Circel) and 55,6% for the CONROL (N). 4B. DAPC of
patients with chronic Chagas cardiomyopathy infected with different DTU’s and CONTROLS: The diagram shows a cluster of 95% for TcI (Blue Circle),
15% for Tc II (Magenta Circle), 86,7% for mix TcI/TcII (Green Circle) and 83,3% for the CONTROL (N).
doi:10.1371/journal.pone.0091154.g004
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complexes, and then recognized by another antibody in solution;
the latter is previously bound to a secondary antibody coupled to
phycoerythrin (PE).
Sample reading was performed in BIO FACS Canto IITM
Becton Dickinson (BD) cytometer and analyzed with eFlowCyto-
mix Pro software (Cat. No. BMS8402FF). After acquiring 30,000
events/microwell, cytokine concentration was analyzed according
to manufacturer’s recommendation. After gating the two bead
sizes on a dot plot with forward scatter (FSC) and side scatter
(SSC), events were plotted according to fluorescence emission at
700 nm (bead-contained fluorochrome, intensity corresponding to
cytokine identity) and at 595 nm (PE emission peak, intensity
corresponding to cytokine concentration). Fluorescence intensity
will further refer to the intensity recorded at 595 nm.
Signatures Analyses
The cytokine profile was first assessed by identifying low and
high cytokine producers, as previously reported [40]. Briefly, after
the establishment of the overall median of Median of Fluorecence
Intensity (MFI), each cytokine subsets from all sub-groups were
tagged as they displayed low or high cytokine production. The
percentage of sub-groups showing high cytokine indexes was
calculated for each one. The ascendant frequency of high cytokine
indexes of controls was then used as the reference cytokine curves
to identify changes in the overall cytokine patterns from all other
sub-groups. Each axis represents the frequency (%) of volunteers
showing high cytokine indexes.
Statistical Analysis
Statistical analyses of the data were carried out using GraphPad
Prism software 5.0 and Statistical Package for the Social Sciences
17, SPSS. Discriminant Analysis of Principal Components (DAPC)
was performed, to assess the association between the different
cytokines and the clinical manifestation of Chagas disease (CARD
or NON-CARD) and/or the variability of T.cruzi (TcI, TcII and
Mixed TcI/TcII). The totals of components considered were able
to explain up to 80% of the model. The analysis of cytokine
signatures was performed using the control cytokine signature as
the reference curve, and significant differences were considered
when the values emerged outside the quartile of the reference
signature.
Supporting Information
File S1 File S1 includes the following: Figure S1.
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grams were plotted using the global median cytokine index as the
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